https://www.insurerbrain.com/w/index.php?action=history&feed=atom&title=Definition%3AGenetic_information 2026-06-13T15:48:52Z Revision history for this page on the wiki MediaWiki 1.43.8 https://www.insurerbrain.com/w/index.php?title=Definition:Genetic_information&diff=9098&oldid=prev 2026-03-11T04:58:42Z

<p>Bot: Creating new article from JSON</p> <p><b>New page</b></p><div>🧬 &#039;&#039;&#039;Genetic information&#039;&#039;&#039; refers to data derived from an individual&#039;s DNA tests, family medical history, or genetic predisposition assessments — data that carries profound implications for how [[Definition:Life insurance | life]], [[Definition:Health insurance | health]], and [[Definition:Disability insurance | disability]] [[Definition:Underwriter | underwriters]] evaluate and classify risk. In the insurance context, the central tension is whether carriers should be permitted to use such information in [[Definition:Risk selection | risk selection]] and [[Definition:Premium | pricing]] decisions, or whether doing so constitutes unfair discrimination against applicants who carry genetic markers for conditions that may never manifest.<br /> <br /> 📜 Regulatory treatment varies significantly by jurisdiction. In the United States, the Genetic Information Nondiscrimination Act (GINA) prohibits [[Definition:Health insurer | health insurers]] and employers from using genetic information for coverage or employment decisions, but notably does not extend to life, disability, or [[Definition:Long-term care insurance | long-term care insurance]]. Some states have enacted broader protections that close this gap. In the United Kingdom, insurers voluntarily agreed under the Code on Genetic Testing to a moratorium — with certain exceptions — on requiring or using predictive genetic test results when [[Definition:Underwriting | underwriting]] most policies. These rules force carriers to rely on conventional [[Definition:Medical underwriting | medical underwriting]] factors rather than genomic data, even as the availability of consumer genetic testing through services like 23andMe has surged.<br /> <br /> ⚠️ The stakes for the insurance industry are significant on both sides of the debate. If applicants possess genetic knowledge that insurers cannot access, [[Definition:Adverse selection | adverse selection]] can intensify — individuals who know they carry high-risk markers may purchase more coverage, while those with favorable profiles opt for less, distorting the [[Definition:Risk pool | risk pool]]. Conversely, unrestricted use of genetic data could render certain populations effectively uninsurable, undermining the social purpose of [[Definition:Insurance | insurance]] and inviting political backlash. As genomic science advances and testing becomes cheaper, insurers, regulators, and ethicists will continue to grapple with where to draw the line between actuarial accuracy and equitable access to coverage.<br /> <br /> &#039;&#039;&#039;Related concepts:&#039;&#039;&#039;<br /> {{Div col|colwidth=20em}}<br /> * [[Definition:Adverse selection]]<br /> * [[Definition:Medical underwriting]]<br /> * [[Definition:Risk classification]]<br /> * [[Definition:Unfair discrimination]]<br /> * [[Definition:Life insurance]]<br /> * [[Definition:Health insurance]]<br /> {{Div col end}}</div>

PlumBot